|
1
|
Arnold M, Pandeya N, Byrnes G, Renehan
PAG, Stevens GA, Ezzati PM, Ferlay J, Miranda JJ, Romieu I, Dikshit
R, et al: Global burden of cancer attributable to high body-mass
index in 2012: A population-based study. Lancet Oncol. 16:36–46.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arenas M, Gascón M, Rovirosa À, Hernández
V, Riu F, López I, Montero A and Sabater S: The effect of
lymphadenectomy and radiotherapy on recurrence and survival in
endometrial carcinoma. Experience in a population reference centre.
Rep Pract Oncol Radiother. 20:50–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iavazzo C, Gkegkes ID and Vrachnis N:
Early recurrence of early stage endometrioid endometrial carcinoma:
Possible etiologic pathways and management options. Maturitas.
78:155–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoo KH and Hennighausen L: EZH2
methyltransferase and H3K27 methylation in breast cancer. Int J
Biol Sci. 8:59–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li LY: EZH2: Novel therapeutic target for
human cancer. Biomedicine (Taipei). 4:12014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis
RT, Wu X, Stack EC, Loda M, Liu T, et al: EZH2 oncogenic activity
in castration-resistant prostate cancer cells is
Polycomb-independent. Science. 338:1465–1469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Curry E, Green I, Chapman-Rothe N,
Shamsaei E, Kandil S, Cherblanc FL, Payne L, Bell E, Ganesh T,
Srimongkolpithak N, et al: Dual EZH2 and EHMT2 histone
methyltransferase inhibition increases biological efficacy in
breast cancer cells. Clin Epigenetics. 7:842015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang YB, Niu HT, Chang JW, Dong GL and Ma
XB: EZH2 silencing by RNA interference inhibits proliferation in
bladder cancer cell lines. Eur J Cancer Care (Engl). 20:106–112.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Behrens C, Solis LM, Lin H, Yuan P, Tang
X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, et al: EZH2
protein expression associates with the early pathogenesis, tumor
progression, and prognosis of non-small cell lung carcinoma. Clin
Cancer Res. 19:6556–6565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H and Zhang R: Role of EZH2 in
epithelial ovarian cancer: From biological insights to therapeutic
target. Front Oncol. 3:472013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bachmann IM, Halvorsen OJ, Collett K,
Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and
Akslen LA: EZH2 expression is associated with high proliferation
rate and aggressive tumor subgroups in cutaneous melanoma and
cancers of the endometrium, prostate, and breast. J Clin Oncol.
24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mannelqvist M, Stefansson IM, Wik E,
Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB
and Akslen LA: Lipocalin 2 expression is associated with aggressive
features of endometrial cancer. BMC Cancer. 12:1692012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou J, Roh JW, Bandyopadhyay S, Chen Z,
Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, et
al: Overexpression of enhancer of zeste homolog 2 (EZH2) and focal
adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol
Oncol. 128:344–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eskander RN, Ji T, Huynh B, Wardeh R,
Randall LM and Hoang B: Inhibition of enhancer of zeste homolog 2
(EZH2) expression is associated with decreased tumor cell
proliferation, migration, and invasion in endometrial cancer cell
lines. Int J Gynecol Cancer. 23:997–1005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jia N, Li Q, Tao X, Wang J, Hua K and Feng
W: Enhancer of zeste homolog 2 is involved in the proliferation of
endometrial carcinoma. Oncol Lett. 8:2049–2054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Cai Q, Godwin AK and Zhang R:
Enhancer of zeste homolog 2 promotes the proliferation and invasion
of epithelial ovarian cancer cells. Mol Cancer Res. 8:1610–1618.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rao ZY, Cai MY, Yang GF, He LR, Mai SJ,
Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, et al: EZH2 supports
ovarian carcinoma cell invasion and/or metastasis via regulation of
TGF-beta1 and is a predictor of outcome in ovarian carcinoma
patients. Carcinogenesis. 31:1576–1583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Smits M, Nilsson J, Mir SE, van der Stoop
PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J,
Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma
resulting in EZH2-induced proliferation, migration, and
angiogenesis. Oncotarget. 1:710–720. 2010.PubMed/NCBI
|
|
21
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu
J: Long non-coding RNA H19 increases bladder cancer metastasis by
associating with EZH2 and inhibiting E-cadherin expression. Cancer
Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Spaderna S, Schmalhofer O, Hlubek F, Berx
G, Eger A, Merkel S, Jung A, Kirchner T and Brabletz T: A
transient, EMT-linked loss of basement membranes indicates
metastasis and poor survival in colorectal cancer.
Gastroenterology. 131:830–840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Z, Zhang X, Gang H, Li X, Li Z, Wang
T, Han J, Luo T, Wen F and Wu X: Up-regulation of gastric cancer
cell invasion by twist is accompanied by N-cadherin and fibronectin
expression. Biochem Biophys Res Commun. 358:925–930. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Völkel P, Dupret B, Le Bourhis X and
Angrand PO: Diverse involvement of EZH2 in cancer epigenetics. Am J
Transl Res. 7:175–193. 2015.PubMed/NCBI
|
|
27
|
Zhang B, Liu XX, He JR, Zhou CX, Guo M, He
M, Li MF, Chen GQ and Zhao Q: Pathologically decreased miR-26a
antagonizes apoptosis and facilitates carcinogenesis by targeting
MTDH and EZH2 in breast cancer. Carcinogenesis. 32:2–9. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY
and Yu Q: Polycomb protein EZH2 regulates E2F1-dependent apoptosis
through epigenetically modulating Bim expression. Cell Death
Differ. 17:801–810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Salazar H, Godwin AK, Daly MB, Laub PB,
Hogan WM, Rosenblum N, Boente MP, Lynch HT and Hamilton TC:
Microscopic benign and invasive malignant neoplasms and a
cancer-prone phenotype in prophylactic oophorectomies. J Natl
Cancer Inst. 88:1810–1820. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY
and Yu Q: Polycomb protein EZH2 regulates E2F1-dependent apoptosis
through epigenetically modulating Bim expression. Cell Death
Differ. 17:801–810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Q, Padi SK, Tindall DJ and Guo B:
Polycomb protein EZH2 suppresses apoptosis by silencing the
proapoptotic miR-31. Cell Death Dis. 5:e14862014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang F, Lv LZ, Cai QC and Jiang Y:
Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation
and invasion in hepatocellular carcinoma cell line Hep3B. World J
Gastroenterol. 21:13268–13276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang FZ, He YY, Wang HH, Zhang HL, Zhang
J, Yan XF, Wang XJ, Che Q, Ke JQ, Chen Z, et al: Mutant p53 induces
EZH2 expression and promotes epithelial-mesenchymal transition by
disrupting p68-Drosha complex assembly and attenuating miR-26a
processing. Oncotarget. 6:44660–44674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH,
Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, et al: MicroRNA-26a
suppresses epithelial-mesenchymal transition in human
hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
J Hematol Oncol. 9:12016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fisher ML, Adhikary G, Grun D, Kaetzel DM
and Eckert RL: The Ezh2 polycomb group protein drives an aggressive
phenotype in melanoma cancer stem cells and is a target of diet
derived sulforaphane. Mol Carcinog. 55:2024–2036. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chang JW, Gwak SY, Shim GA, Liu L, Lim YC,
Kim JM, Jung MG and Koo BS: EZH2 is associated with poor prognosis
in head-and-neck squamous cell carcinoma via regulating the
epithelial-to-mesenchymal transition and chemosensitivity. Oral
Oncol. 52:66–74. 2016. View Article : Google Scholar : PubMed/NCBI
|
